More Business Wire
View Older Stories View Newer Stories-
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
-
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
-
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
-
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
-
13th Annual Energy Day Festival Sparks STEM Interest Among Houston Students
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
-
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
-
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTI
-
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
-
University of Phoenix College of Social and Behavioral Sciences Leadership Publishes White Paper on Trauma-Informed Education
-
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical O
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
-
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
-
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
-
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
-
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
-
CORRECTING and REPLACING Alliant Insurance Services Expands Transportation Risk and Cross-Border Expertise in Texas through Strategic Acquisition and Key Hires
-
Light & Wonder Statement on NV Legal Proceedings
-
Typhoon Recovery: U-Haul Offers 30 Days Free Storage across Alaska
-
Kolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure
-
STEP Energy Services Ltd. Agrees to $5.50 Per Share Take Private Transaction With Funds Advised by ARC Financial Corp.
-
Asteria Announces New Animated Short All Heart From Oscar-Winning Filmmakers Michael Govier & Will McCormack and Executive Producer Natasha Lyonne
-
Sensient Announces Conference Call
-
SameDayAbortionPills Notes That While Major Pharmacies Strive to Dispense Abortion Pills Consistently, Occasional Refusals Still Occur Due to Individual Human Factors
-
ALLO Enables Equal Access To Secure Wi-Fi for All Students With Calix SmartTown for Education
-
Granite REIT Declares Distribution for October 2025
-
GreenFirst Welcomes the Restart of Operations at One of Its Key Customers, Kap Paper Inc.
-
AM Best Affirms Credit Ratings of AMEX Assurance Company
-
Arctera Named a Leader in the Gartner® Magic Quadrant™ for Digital Communications Governance and Archiving Solutions
-
The Chequit Announces Seasonal Winter Closure
-
FCPT Announces Acquisition of a Heartland Dental Property for $3.3 Million
-
PFD, PFO, FFC, FLC and DFP Announce Dividends for November
-
Delek US Holdings to Host Third Quarter 2025 Conference Call on November 7th
-
Eaton to announce third quarter 2025 earnings on November 4, 2025
-
Delek Logistics Partners, LP to Host Third Quarter 2025 Conference Call on November 7th
-
RiverNorth Opportunities Fund, Inc. and RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. Announce Preferred Dividends
-
KBRA Assigns AA+ Rating to North Slope Borough, AK General Obligation Bonds, Series 2025
-
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
-
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
-
Permianville Royalty Trust Announces Monthly Cash Distribution
-
Fubo Announces Inducement Grants Under NYSE Listing Rule 303A.08
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Humankind Investments Announces Liquidation of the Humankind US Stock ETF
-
Venture Global, Inc. Announces Timing of Third Quarter 2025 Earnings Release and Conference Call
-
Comfort Systems USA Announces Third Quarter 2025 Conference Call and Webcast
